| Figure 1. The Network Theory. Antibody
1 (Ak-1) has a structure in its variable (V) region which can bind the antigen.
The V-region of Ak-1 contains unique structures which stimulate the production
of various anti-antibodies (Ak-2). Some Ak-2 express V-region structures which
mimic the antigen and which therefore can stimulate Ak-1 production. Each
antibody generation induces the production of still another and larger set of
anti-antibodies in a cascade-like manner. The various sets of antibodies stimulate
or suppress the production of each other in a complex network. Under normal conditions
the network is balanced. However, the equilibrium is disturbed when an antigen
is introduced and binds to Ak-1. The immune system attempts to restore the balance,
i.e. it leads to an immune response. Some examples where the network
theory has been applied to experimental and clinical medicine are given in the
following. 1. Infectious diseases. Anti-antibodies have been
used in animals as a kind of vaccine against parasitic infections (trypanosomiasis),
urinary tract infections, hepatitis and other infectious diseases.
2. Allergy. Anti-pollen antibodies may elicit allergic symptoms when an
allergic person is exposed to pollen. The production of anti-pollen antibodies
has been prevented in animals by anti-antibodies. 3. Autoimmune
disease. Autoimmune disease may be caused by antibodies directed against the
body's own tissues. Experimental autoimmune disease has been successfully treated
with anti-antibodies. 4. Transplantation. Anti-antiimmunity
may be important in organ transplantation by contributing to immunological tolerance
against antigen on the foreign graft. 5. Endocrinology. Anti-antibodies
against hormones and hormone receptors may prevent binding of the hormone to the
receptors. This has been described for insulin and its receptor.
6. Tumours. Anti-antibodies have been attempted as treatment of certain
tumours of the human immune system. Hybridoma - a
technique for eternal production of monoclonal antibodies in cell cultures
Besides gene technology, which has already been honoured by several Nobel
Prizes, the hybridoma technique represents the most important methodological advance
within the field of biomedicine during the 1970s. The development of this technique
is based on several observations concerning basic biological phenomena.
There are cells in the body - immune lymphocytes - which can produce millions
of different antibodies. However, each single cell can only produce antibodies
with a certain predetermined specificity. A prerequisite for the formation of
a multitude of antibodies is, therefore, the existence of an excess of lymphocytes.
If the body is exposed to a certain foreign antigen there may be stimulation of
a lymphocyte which fortuitously has been endowed with the capacity to identify
this particular antigen. This lymphocyte then starts to divide and forms a clone
of cells which produces identical - monoclonal - antibodies. The
development of a clone of cells in connection with a normal immune response occurs
under carefully controlled conditions. In rare cases, however, the body loses
control over a clone of antibody producing cells. This may lead to formation of
a special type of tumour (myeloma). Myeloma cells usually retain their capacity
to produce a certain antibody, but because of the accidental emergence of the
tumour one normally does not know with which antigen this antibody reacts.
White blood cells responsible for producing antibodies are highly specialized
cells. As a consequence they lack capacity to survive for a longer time if they
are removed from the body and incubated in a tissue culture medium. In contrast,
myeloma cells can occasionally be cultivated continuously. Since long, biomedical
research workers have nourished the dream to be able to propagate clones of cells
which produce antibodies with predetermined specificity. This dream materialized
when Georges J.F. Köhler and César Milstein in 1975 introduced the
so-called hybridoma technology for production of monclonal antibodies. The principle
features of the hybridoma technology is as follows (Figure 2). |